<DOC>
	<DOC>NCT01023386</DOC>
	<brief_summary>This study investigates the pharmacokinetics of YM155, identifies the metabolic profile of YM155 and evaluates the safety and tolerability of YM155 after a 3-hour infusion in patients with advanced cancer</brief_summary>
	<brief_title>A Clinical Pharmacological Study of YM155 After Intravenous Infusion in Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<criteria>Patients with histologically or cytologically confirmed locally advanced or metastatic solid tumors or nonHodgkin's lymphomas for which YM155 has the potential, based on preclinical and/or clinical data, to show efficacy, namely: castrate resistant prostate cancer nonsmall cell lung cancer metastatic melanoma muscle invasive bladder cancer follicular lymphoma diffuse large Bcell lymphoma Life expectancy ≥ 3 months; and Performance status (PS) ≤ 2 on the Eastern Cooperative Oncology Group (ECOG) scale at baseline Radiotherapy, major surgery, hormonal therapy, and chemotherapy within 4 weeks prior to the first dose of study medication and 6 weeks in the case of mitomycinC or nitrosourea Previous therapy with YM155 Patients with renal, hepatic or colorectal cancers Inadequate bone marrow, renal and/or hepatic function History of being treated for other malignancy within 5 years except for treated basal or squamous cell carcinoma of the skin Participation in any clinical study within 4 weeks prior to start of the first dose of study medication Known brain or leptomeningeal metastases Active uncontrolled systemic infection at baseline</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>YM155</keyword>
	<keyword>Mass-balance</keyword>
	<keyword>Phase I</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>